CD8A and melanoma: On the other hand, therapy with the anti CTLA-4 monoclonal antibody tremelimumab was shown to restore CD4+ and CD8+ T-cells in 7 of 10 patients with pretreated advanced melanoma and severe lymphopenia [20].